Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use

06 Aug 2024 Planned End Date changed from 10 Jul 2024 to 10 Jul 2025.
07 Jun 2022 Results of a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 studies assessed the the association of intrinsic subtypes and gene expression signatures with pathologic complete response and event-free survival presented at the 58th Annual Meeting of the American Society of Clinical Oncology
01 Oct 2021 Results (n=539) of an analysis assessing predictors of nodal pathologic complete response among patients from two clinical studies: CALGB40601 and CALGB40603 published in the Annals of Surgical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com